The analysis guide adjusts its motivated value from SEK 20 to the range SEK 16-23 for the medical technology company Synthetic MR, according to a commissioned analysis.
“This is a consequence of deferred revenues and an increased risk premium until we see that the partly new organization in the US continues to deliver the growth we expect and that the integration with the recently acquired Combinostics goes according to plan. The communication in the coming quarters will be very interesting to follow as our main track includes a clear recovery in the company’s sales in 2025 and a relatively smooth integration of Combinostics,” it says.
The analyst guide continues to believe that the company will continue on its growth journey over the next year.
The share rises 2.8 percent to SEK 4.79 after falling sharply recently in the wake of the Q3 report.